VRP is developing first-in-class drugs to treat unmet medical needs in respiratory disease. Over the last two years’ VRP has reported positive outcomes from a five stage Phase I/IIa programme which has de-risked RPL554 significantly. This drug has been shown to have strong bronchodilatory and anti-inflammatory effects with minimal side effects. New funds will support a broad programme of Phase II trials for maintenance therapy via a nebulizer and hospital use. It will certainly attract
20 Jun 2016
Funding secured for Phase IIb trial
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Funding secured for Phase IIb trial
Verona Pharma plc Sponsored ADR (VRNA:NAS) | 0 0 0.0%
- Published:
20 Jun 2016 -
Author:
Martin Hall -
Pages:
4
VRP is developing first-in-class drugs to treat unmet medical needs in respiratory disease. Over the last two years’ VRP has reported positive outcomes from a five stage Phase I/IIa programme which has de-risked RPL554 significantly. This drug has been shown to have strong bronchodilatory and anti-inflammatory effects with minimal side effects. New funds will support a broad programme of Phase II trials for maintenance therapy via a nebulizer and hospital use. It will certainly attract